Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could two old drugs beat one for migraine prevention?

NCT ID NCT07655700

Disease control Sponsor: Chittagong Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether taking two inexpensive migraine prevention drugs together works better than taking either one alone. Adults aged 18 to 55 who have at least four migraines per month will receive propranolol, flunarizine, or both for 12 weeks. The goal is to see which approach reduces monthly migraine days most effectively and safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
propranolol and flunarizine (alone or combined)
What this could lead to
If the combination works better, it could offer a more effective, affordable option for preventing frequent migraines without needing expensive new drugs.
What could go wrong
This is a single-center, open-label trial, so results may not apply broadly. Side effects from either drug or the combination could limit use, and the 12-week duration may not reflect long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 177 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants aged 18 to 55 years. 2. Diagnosis of episodic migraine, defined according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria. 3. Participants experiencing 4 or more migraine attacks per month. 4. Willingness to provide written informed consent to participate in the study. Exclusion Criteria: 1. Comorbidities: * Presence of other primary headache disorders, chronic migraine, hemiplegic migraine, basilar migraine or any secondary headache disorder. * Known serious underlying systemic diseases including Cardiac disease (Heart failure, Heart Block, Arrhythmia), Renal dysfunction, Liver dysfunction, Pulmonary disease (Asthma, COPD), Peripheral vascular disease, Extrapyramidal disease (Parkinson disease, Chorea, Dystonia). * Pregnancy or breastfeeding. * Psychiatric illness (Depression, Psychosis, Obsessive compulsive disorder). 2. Medications: * Received migraine prophylactic medication within 60 days prior to screening. * Use of specific contraindicated medications, including beta-blockers or calcium channel blockers, except as part of the study treatments. 3. Non-compliance: * Inability or unwillingness to comply with study protocols, including maintaining a headache diary or attending follow-up visits. 4. History of Allergies: * Known hypersensitivity to propranolol, flunarizine 5. Substance Use: * Current substance abuse

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Episodic migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Migraine prophylaxis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chittagong Medical College

    Chittagong, 4203, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.